FilingReader Intelligence
Rossari Biotech reports 11% revenue growth in Q1
July 20, 2025 at 08:09 AM UTC•By FilingReader AI
Rossari Biotech reported Q1 FY26 consolidated revenues of INR 543.7 crore, an 11% increase year-over-year. EBITDA rose 4.6% to INR 67.9 crore, with PAT at INR 33.6 crore.
Standalone revenue grew 21.6% to INR 365.8 crore, with EBITDA up 10.3% to INR 43.9 crore. The HPPC and AHN divisions achieved growth of 16% and 12% respectively.
Capacity expansion projects are progressing, with commissioning scheduled over the coming quarters, expected to drive growth from FY27 onwards.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:ROSSARI•Bombay Stock Exchange
News Alerts
Get instant email alerts when ROSSARI BIOTECH publishes news
Free account required • Unsubscribe anytime